Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome

Crossover study Tetrahydrocannabinol
DOI: 10.1056/evidoa2300012 Publication Date: 2023-06-07T13:00:38Z
ABSTRACT
BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) that coadministration cannabidiol (CBD) improves the side-effect profile safety. METHODS: In this double-blind, crossover trial, participants with severe were randomly assigned to a 6-week treatment period escalating doses an oral oil 5 mg/ml THC CBD, followed course placebo, or vice versa, separated 4-week washout period. The primary outcome was total tic score on Yale Global Tic Severity Scale (YGTSS; range, 0 50 [higher scores indicate greater severity symptoms]). Secondary outcomes included video-based assessment tics, global impairment, anxiety, depression, obsessive-compulsive symptoms. Outcomes correlated plasma levels cannabinoid metabolites. A computerized cognitive battery administered at beginning end each RESULTS: Overall, 22 (eight female participants) enrolled. Reduction in (at week 6 relative baseline) as measured YGTSS 8.9 (±7.6) active group 2.5 (±8.5) placebo group. linear mixed-effects model, there significant interaction (active/placebo) visit number (coefficient = −2.28; 95% confidence interval, −3.96 −0.60; P=0.008), indicating decrease (improvement) tics under treatment. correlation between 11-carboxy-tetrahydrocannabinol outcome, which attenuated after exclusion outlier. most common adverse effect headache (n=7); period, it difficulties, including slowed mentation, memory lapses, poor concentration (n=8). CONCLUSIONS: syndrome, CBD reduced may reduce impairment due disorder; although some associated concentration. (Funded Wesley Medical Research Institute, Brisbane, Lambert Initiative for Cannabinoid Therapeutics, philanthropically-funded research organization University Sydney, Australia; Australian New Zealand Clinical Trials Registry number, ACTRN12618000545268.)
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (12)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....